ACR Appropriateness Criteria® Spinal Bone Metastases by Lo, Simon Shek-Man et al.
Special Report
ACR Appropriateness Criteria Spinal Bone Metastases
Expert Panel on Radiation Oncology–Bone Metastases: Simon Shek-Man Lo, MB, ChB,1
Stephen T. Lutz, MD, MS,2 Eric L. Chang, MD,3 Nicholas Galanopoulos, MD,4 David D. Howell, MD,5
Edward Y. Kim, MD,6 Andre A. Konski, MD,7 Neeta D. Pandit-Taskar, MD,8 Peter S. Rose, MD,9
Samuel Ryu, MD,10 Larry N. Silverman, MD,11 Andrew E. Sloan, MD,12 and Catherine Van Poznak, MD13
Abstract
The spine is a common site of involvement in patients with bone metastases. Apart from pain, hypercalcemia, and
pathologic fracture, progressive tumor can result in neurologic deterioration caused by spinal cord compression or
cauda equina involvement. The treatment of spinal bone metastases depends on histology, site of disease, extent of
epidural disease, extent of metastases elsewhere, and neurologic status. Treatment recommendations must weigh
the risk-benefit profile of external beam radiation therapy (EBRT) for the particular individual’s circumstance,
including neurologic status, performance status, extent of spinal disease, stability of the spine, extra-spinal disease
status, and life expectancy. Patients with spinal instability should be evaluated for surgical intervention. Research
studies are needed that evaluate the combination or sequencing of localized therapies with systemic therapies
including chemotherapy, hormonal therapy (HT), osteoclast inhibitors (OI), and radiopharmaceuticals. The roles of
stereotactic body radiation therapy (SBRT) in the management of spinal oligometastasis, radioresistant spinal
metastasis, and previously irradiated but progressive spinal metastasis are emerging, but more research is needed
to validate the findings from retrospective studies. The American College of Radiology Appropriateness Criteria
are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary
expert panel. The guideline development and review include an extensive analysis of current medical literature
from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi)
to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is
lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Summary of Literature Review
Introduction/Background
The axial skeleton is a common site of involvement inpatients with bone metastases. Apart from pain, hyper-
calcemia, and pathologic fracture, progressive tumor can re-
sult in neurologic deterioration caused by spinal cord
compression or cauda equina involvement. The treatment of
spinal bone metastases depends on many factors including
histology, site of disease, extent of epidural disease, extent of
metastases elsewhere, and neurologic status. Ideally, patients
with spinal bone metastases are evaluated by an interdisci-
plinary team including a combination of radiation oncolo-
gists, medical oncologists, spine surgeons, pain medicine
specialists, interventional radiologists, psychiatrists, and
palliative care professionals. Treatment recommendations
must weigh the risk-benefit profile of radiation therapy (RT)
for the particular individual’s circumstance, including
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neurologic status, performance status, extent of spinal dis-
ease, stability of the spine, extra-spinal disease status, and life
expectancy. Patients with spinal instability should be evalu-
ated for surgical intervention.1 Research studies are needed
that evaluate the combination or sequencing of localized
therapies such as surgery and external beam radiotherapy
(EBRT) with systemic therapies including chemotherapy,
hormonal therapy (HT), osteoclast inhibitors (OI), and
radiopharmaceuticals.2–4
Under current practice, systemic chemotherapy and/or HT
andOI are frequently administered when asymptomatic bone
metastases are first diagnosed. EBRT is usually delayed until
the metastatic disease progresses and causes significant pain
or creates a risk for pathologic fracture or spinal cord com-
pression. The use of radiopharmaceuticals is generally con-
sidered in a small fraction of patients with persistent
multifocal sites of pain or recurrence of pain in a previously
irradiated site.5
Stereotactic body radiation therapy (SBRT) is an emerging
therapy for spinal metastasis as primary treatment, postop-
erative treatment, or salvage treatment after prior EBRT or
spinal cord compression.6,7 Preliminary results based on ret-
rospective studies and a small number of prospective studies
appear to be promising, but the follow-up intervals for most
studies are short and the reported endpoints are not uniform,
rendering comparison with other conventional therapies dif-
ficult. A limited number of prospective studies and clinical
trials show promising results.6,8 SBRT’s roles in the manage-
ment of spinal oligometastasis, radioresistant spinal metas-
tasis, and previously irradiated but progressive spinal
metastasis are emerging, but more research is needed to val-
idate the findings from retrospective studies. Logistically, the
treatment planning and delivery processes require much
more time and resources.
Epidural spinal cord compression represents a special sit-
uation for treating spinal metastasis and is an oncologic
emergency.9 The key goal of the treatment is prompt de-
compression of the spinal cord in order to prevent further
deterioration of neurologic function or to reverse the neuro-
logic deficits. This can be accomplished by surgical decom-
pression or EBRT.9 For most solid tumors, except radio- and
chemo-sensitive tumors such as germ cell tumors and small-
cell carcinomas, surgical decompression followed by EBRT
has been demonstrated to yield superior functional outcomes
compared with EBRT alone.10,11 For patients who have poor
performance status or are not suitable for surgery, EBRT is
regarded as a reasonable option, although there is some
debate as to optimal dose schedules and fractionation.9,12
Hematologic tumors such as lymphoma and plasma cell
tumors/myeloma are radiosensitive, and EBRT alone is
effective in decompressing the spinal cord. SBRT has been
used to decompress spinal cord compression, but data in the
literature are limited.12,13 More research is needed to define its
role in managing spinal cord compression.
Variant 1 Discussion
This is a case of spinal cord compromise involving a region
that has not been previously irradiated. This patient is ex-
pected to have very poor prognosis, and local palliative EBRT
to prevent lower-extremity paralysis before referral for hos-
pice care is regarded as the most appropriate treatment plan.
Medications to aid symptom control may include steroids and
analgesics. Moderate- to high-dose steroids are typically used
in managing spinal cord involvement. Hospice placement
after EBRT is favored to avoid the logistic difficulties of
coming to the radiation center for EBRT, although some
hospices accommodate palliative EBRT.14
Due to the spinal cord compression and the bulk of disease
with paraspinous involvement, computed tomography (CT)
simulation and EBRT are recommended, ranging from a sin-
gle 8Gy fraction to 30Gy10 fractions. Given the poor prog-
nosis, a single dose of 8Gy is deemed as appropriate as 20Gy
in 5 fractions and 30Gy in 10 fractions, and longer fraction-
ation regimens such as 35Gy in 14 fractions and 40Gy in 20
fractions are deemed not to be appropriate because long-term
toxicities are not an active concern in this case.15–17 Fluoro-
scopic simulation is regarded as a reasonable alternative.
Clinical simulation, defined as setting up of a patient at the
treatment machine without kilovoltage films, is usually not
preferred. Common EBRT field arrangements, anterior/pos-
terior (AP/PA), PA and posterior obliques alone, are consid-
ered appropriate. Highly conformal approaches such as
SBRT, intensity-modulated radiation therapy (IMRT), and
protons are considered inappropriate given the expected poor
prognosis, the need for prompt treatment, the numerous
levels involved, and the limited data on these approaches.18
Surgical intervention is not considered appropriate due to the
expected poor prognosis, the multiple vertebral levels in-
volved, and the limited life expectancy. There are concerns
regarding the futility of administering further chemotherapy,
given the prior treatment history and the extent of tumor
burden, although the patient may be considered for an ex-
perimental protocol if it is available and the patient is deemed
eligible.19,20 (See Table 1.)
Variant 2 Discussion
There is a localized symptomatic region of bonemetastases.
This patient has a fairly good performance status and verte-
bral involvement. She has incurable disease, and the goals of
care are palliative. The use of EBRT with analgesics, initiation
of HT, and OI,21 is regarded as the most appropriate treat-
ment. HT, like localized RT, incurs limited morbidity while
treating symptomatic disease and limiting consequential
disease progression.22 The use of RT to control pain and tumor
burden constitutes a skeletal-related event (SRE). This scenario
warrants the use of an OI to further reduce the risk of addi-
tional SREs.12 In light of the slight risk of jaw osteonecrosis
associated with OI administration, a pretreatment dental
evaluation to assess dentition and potential risk prior to OI use
might be necessary. The addition of chemotherapy after EBRT
and HT (given sequentially), with or without OI is regarded as
less appropriate due to the considerable morbidity of chemo-
therapy, limited survival benefit, and quality of life during the
course of chemotherapy given the lack of visceral tumor bur-
den and the expected symptom controlwith EBRT,HT, andOI.
For this estrogen receptor (ER) positive and progesterone re-
ceptor (PR) positive tumor, the use of chemotherapy (with or
without OI) and EBRT without HT is deemed inappropriate.
Systemic radiopharmaceuticals and surgical intervention are
regarded as the least appropriate. For this clinical situation, life
expectancy may potentially be measured in years; hence hos-
pice is not typically an appropriate next step.
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HT and OI with analgesics may be considered options for
the initial intervention. However, EBRT offers the patient an
excellent likelihood of expedient pain control and can be used
in conjunction with HT, OI, and analgesics and is a favored
approach due to the magnitude of her pain. In this symp-
tomatic spine lesion where disease progression under sys-
temic therapy alone could incur the risk of spinal cord
compression, the benefit of adding EBRT to any systemic
regimen is emphasized. If EBRT is not administered to the
spine at this time, then very close monitoring of the patient
would be required to monitor for pain as well as early
symptoms of spinal cord compression.
The RT dose fractionation prescribed for spinal metastases
varies from those for long bones. Fractionation schedules
ranging from a single 8Gy fraction to 35Gy in 14 fractions are
all considered appropriate, whereas 40Gy in 20 fractions is
considered less appropriate due to the protracted length of
therapy. CT simulation, to accurately include the involved
vertebrae and account for body habitus in EBRT dose calcu-
lation is most desirable. Fluoroscopic simulation is regarded
as a reasonable alternative. Common EBRT field arrange-
ments, AP/PA and PA alone, are considered appropriate.
Posterior oblique treatment is also an appropriate alternative
if the kidneys can be spared, as it is an easy, relatively con-
formal dosimetric approach that can spare the skin if spinal
surgery ever comes into play in the later course of disease. The
treating physician will need to judge the risk and benefit of
each technique on each individual patient. However, more
sophisticated, highly conformal approaches such as SBRT,
IMRT, and protons are considered not necessary. Low- to
moderate-dose steroids are often used during the course of
radiation to vertebral metastases in the absence of spinal cord
involvement. (See Table 2.)
Variant 3 Discussion
This patient presents with epidural spinal cord compres-
sion at T7 and is without a history of prior therapy for his
Table 1. Variant 1
Clinical Condition: Spinal Bone Metastases
A 55-year-old patient with lung cancer with KPS 70 and a history of prior EBRT for a Pancoast tumor, including vertebral
levels C7-T4. He received three lines of systemic therapy prior to presenting with symptomatic vertebral metastases (pain
scale 6 out of 10) with paraspinous soft-tissue extension from T6–10 with spinal cord compression and mild weakness.
Diffuse metastatic disease is noted on bone scan, and multiple small liver metastases are evident on CT of abdomen.
Treatment Rating Comments
Hospice after EBRT 8
EBRT alone 8
Direct hospice placement 5 Given the expected poor prognosis, direct hospice placement
may be appropriate if pain can be adequately controlled by
pharmacologic means.
Chemotherapy and EBRT 3 After progression of disease on third-line therapy there are
insufficient data to suggest benefit from additional lines
of systemic treatment. Consideration for participation in
clinical trials may be given for select individuals.
Chemotherapy and OI and EBRT 2
Chemotherapy alone 2
Systemic radiopharmaceuticals 2
Surgical intervention 2
Chemotherapy and OI 2
Radiation therapy dose
8Gy/1 fraction 8
20Gy/5 fractions 8
30Gy/10 fractions 8
35Gy/14 fractions 3
40Gy/20 fractions 2
Treatment planning
CT simulation 8
Fluoroscopic simulation 8
Clinical simulation 3
Posterior field only 7 The depth of the spinal segments involved and photon energy
used are to be considered if this technique is used.
Anterior/posterior fields 7
Posterior obliques 7
SBRT 2
IMRT 2
Proton therapy to the bone metastasis 1
Rating Scale: 1,2,3: usually not appropriate; 4,5,6: may be appropriate; 7,8,9: usually appropriate.
CT, computed tomography; EBRT, external beam radiation therapy; ER, estrogen receptor; IMRT, intensity-modulated radiation therapy;
KPS, Karnofsky performance status; OI, osteoclast inhibitors; PR, progesterone receptor; SBRT, stereotactic body radiation therapy.
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multiple myeloma. The main goals of treatment are to de-
compress the spinal cord and to control the pain. High- to
moderate-dose steroid therapy should be started promptly to
decrease cord edema/inflammation and act therapeutically
against myeloma. Because plasma cell tumors are very ra-
diosensitive even to a low to moderate dose of radiation,
the recommended treatment is emergent EBRT.9 AddingOI to
the treatment of multiple myeloma reduces pathologic ver-
tebral fractures, SREs, and pain, and it can be considered
in conjunction with EBRT.23 In light of the slight risk of
jaw osteonecrosis associated with OI administration, a pre-
treatment dental evaluation to assess dentition and poten-
tial risk prior to OI use might be necessary. OI with
pamidronate or zoledronic acid are FDA approved for use
in multiple myeloma, but not denosumab. Surgical interven-
tion is generally not required unless present or impending
spinal instability is contributing to the cord compression.
Kyphoplasty procedures may be considered for pathologic
vertebral compression fractures but are not indicated in the
setting of spinal cord compression.24 Radiopharmaceuticals
are used in multiple myeloma clinical trials, in association
with stem cell transplantation.25 The presence of systemic
disease coupled with the patient’s reasonably good perfor-
mance status suggests that systemic treatment should be
considered.
Although there are no definitive data to suggest the
most appropriate RT dose, fractionation schedules rang-
ing from a single 8Gy fraction to 40 Gy in 20 fractions are
all considered appropriate. Given the fact that the patient
is relatively young and has good performance status, the
life expectancy can be estimated in years. For this reason,
more fractionated regimens, such as 30 Gy in 10 fractions,
35Gy in 14 fractions, or 40Gy in 20 fractions, are favored.
CT simulation to accurately include the involved verte-
brae and account for body habitus in EBRT dose calculation
is most desirable. Fluoroscopic simulation is regarded as a
Table 2. Variant 2
Clinical Condition: Spinal Bone Metastases
A 55-year-old woman with ER positive/PR positive and HER2 negative breast cancer, and new metastases with
symptomatic (pain scale 7 out of 10) vertebral metastases at T12, L1, and L2, with no compression fracture or canal
involvement. In addition, she has diffuse asymptomatic metastases on bone scan, rising CEA and no prior EBRT to spine.
KPS 80, with no visceral tumor burden. No prior HT.
Treatment Rating Comments
HT and EBRT 8
HT and OI and EBRT 8
Chemotherapy and HT and EBRT 5
Chemotherapy and HT and OI and EBRT 5
Chemotherapy and EBRT 3
HT alone 3
Chemotherapy alone 3
EBRT alone 3
Systemic radiopharmaceuticals alone 2
Surgical intervention 2
Direct hospice placement 2
Hospice after EBRT 2
Radiation therapy dose
8Gy/1 fraction 8
20Gy/5 fractions 8
30Gy/10 fractions 8
35Gy/14 fractions 5
40Gy/20 fractions 3
Treatment planning
CT simulation 8
Fluoroscopic simulation 8
Clinical simulation 3
Posterior field only 7 The depth of the spinal segments involved and photon
energy used are to be considered if this technique is used.
Anterior/posterior fields 8
Posterior obliques 7 This technique helps preserve the skin if surgical intervention
of the spine come into play in later course of disease, but it is
only deemed appropriate if the kidneys can be spared.
SBRT 3
IMRT 2
Proton therapy to the bone metastasis 2
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CEA, carcinoembryonic antigen; CT, computed tomography; EBRT, external beam radiation therapy; ER, estrogen receptor; HT, hormonal
therapy; IMRT, intensity-modulated radiation therapy; KPS, Karnofsky performance status; OI, osteoclast inhibitors; PR, progesterone
receptor; SBRT, stereotactic body radiation therapy.
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reasonable alternative. Common EBRT field arrangements,
AP/PA, PA alone, and posterior obliques are considered
appropriate. A posterior oblique treatment approach is
favored, as it is an easy, relatively conformal dosimetric
approach that can reduce the dose administered to the skin
and this may be beneficial if spinal surgery comes into play
in the later course of disease. However, it can also result in
higher lung dose. The treating physician will need to judge
the risk and benefit of each technique in each individual
patient. More sophisticated, highly conformal approaches
such as SBRT, IMRT, and protons are considered insuffi-
ciently studied and therefore unjustified. Furthermore,
multiple myeloma is very radiosensitive, rendering radia-
tion dose escalation using advanced technology unneces-
sary for palliation of pain and spinal cord compression. (See
Table 3.)
Variant 4 Discussion
The patient’s systemic tumor burden appears stable, and
his only symptomatic site is that of the T7 lesion. The case
raises the issue of reirradiation of the spine. Reirradiation
using EBRT poses an increased risk of radiation myelitis
should the patient’s lifespan exceed 6 months. Means to treat
this symptomatic T7 lesion include surgery, reirradiating, or
systemic anticancer interventions with chemotherapy or
radiopharmaceuticals. Steroids, OI, and analgesics may im-
prove pain control and should be used. Surgery may be
considered if the adjacent, irradiated bone appears stable and
the patient’s life expectancy is > 3–6 months. The decision to
proceed with surgery in this situation is very nuanced; pa-
tients with vertebral body compression fracture alonewithout
significant mechanical instability are often helped with
Table 3. Variant 3
Clinical Condition: Spinal Bone Metastases
A 54-year-old man presents with newly diagnosed multiple myeloma. He develops mild bilateral lower-extremity
weakness (motor power 5 minus out of 5) from an epidural spinal cord compression at T7 seen on MRI, associated
with severe pain (scale 8 of 10). KPS 80. Skeletal survey reveals several other sites of asymptomatic lytic metastases.
Treatment Rating Comments
Steroid therapy and EBRT, followed by OI
and chemotherapy
8 EBRT sequentially with systemic therapy.
Steroid therapy and EBRT, followed by
chemotherapy
7
Steroid therapy and EBRT, followed by OI 6
Steroid therapy and EBRT 6
Steroid therapy and OI and chemotherapy 3
Steroid therapy and chemotherapy 3
Steroid therapy and OI 3
EBRT alone 3
Steroid therapy alone 2
OI alone 2
Hospice after EBRT 2 Life expectancy would be expected to be > 6 months.
Observation 1
Systemic radiopharmaceuticals alone 1
Direct hospice placement 1 Life expectancy without treatment still could be > 6 months,
although paraplegia would be expected to occur.
Radiation therapy dose
8Gy/1 fraction 6
20Gy/5 fractions 8
30Gy/10 fractions 8
35Gy/14 fractions 6
40Gy/20 fractions 5
Treatment planning
CT simulation 8
Fluoroscopic simulation 8
Clinical simulation 5
Posterior field only 6 The depth of the spinal segments involved and photon
energy used are to be considered if this technique is used.
Anterior/posterior fields 7
Posterior obliques 7 This technique can help preserve skin if spinal surgery comes
into play in later course disease but it will result in higher
lung doses.
SBRT 2
IMRT 2
Proton therapy to the bone metastasis 1
Rating Scale: 1,2,3: usually not appropriate; 4,5,6: may be appropriate; 7,8,9: usually appropriate.
CT, computed tomography; EBRT, external beam radiation therapy; IMRT, intensity-modulated radiation therapy; KPS, Karnofsky
performance status; MRI, magnetic resonance imaging; OI, osteoclast inhibitors; SBRT, stereotactic body radiation therapy.
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vertebral augmentation procedures such as kyphoplasty or
vertebroplasty.26 Patients with involvement of the vertebral
body and posterior elements, other evidence of spinal insta-
bility, or refractory symptoms may benefit from surgical in-
tervention if their performance status allows. There is little
information to provide guidance on reirradiation of spinal
metastases. Goals of treatment include obtaining pain relief
while minimizing the risk of radiation myelitis. Highly con-
formal techniques such as proton therapy, SBRT, or IMRT can
be considered if they are available and if sustained positioning
is achievable for the patient. Ideally, the patient can enroll in a
clinical trial, if one is available. Different fractionation regi-
mens have been used in SBRT for reirradiation of recurrent
spinal metastasis, and they are all deemed appropriate pro-
vided the cord tolerance can be respected.27 Surgery can
provide rapid relief of debilitating pain and may be consid-
ered given the patient’s good performance status. Because
there is no spinal canal involvement in this case, systemic
Table 4. Variant 4
Clinical Condition: Spinal Bone Metastases
A 72-year-old man with non-small-cell lung cancer, 2 years status post right upper lobectomy with a KPS of 80. He received
previous RT to the T5-T8 spine 10 months ago to 30Gy in 10 fractions. He also received two lines of systemic chemotherapy.
Now he presents with debilitating pain (pain scale 8 out of 10) from recurrent disease at T7 with no canal involvement.
Diffuse asymptomatic bone metastasis, stable on bone scan with no visceral metastases.
Treatment Rating Comments
Surgical intervention alone 6 Surgery may be considered if the adjacent, irradiated
bone appeared stable and the patient’s life
expectancy was > 3–6 months.
EBRT alone 6 EBRT in the form of SBRT or IMRT if they are available
and sustained positioning is achievable for the
patient.
Surgical intervention and EBRT 6 If life expectancy > 3–6 months; EBRT in the form of
SBRT if they are available and sustained positioning
is achievable for the patient. See comments about
surgery in text.
Surgical intervention and EBRT and systemic
radiopharmaceuticals
5 If life expectancy > 3–6 months; EBRT in the form of
SBRT if they are available and sustained positioning
is achievable for the patient.
Surgical intervention and systemic
radiopharmaceuticals
5
Hospice after treatment (surgery or SBRT) of the spine 5
Systemic radiopharmaceuticals alone 3
Direct hospice placement 3
Chemotherapy 4 Third-line chemotherapy with erlotinib may be
considered for individuals who have a good
performance status and who have not had prior
exposure to erlotinib or gefitinib. There are
insufficient data addressing use of additional
cytotoxic drugs; considerations may be given to
clinical trials and best supportive care.
OI alone 3
SBRT dose
12–18Gy/1 fraction 7 Spinal cord tolerance permitting.
21–27Gy/3 fractions 7 Spinal cord tolerance permitting.
20–30Gy/5 fractions 7 Spinal cord tolerance permitting.
Treatment planning
CT simulation 9 CT simulation is mandatory if SBRT is offered because
sophisticated dose planning is required.
Fluoroscopic simulation 3
Clinical simulation 3
Posterior field only 3
Anterior/posterior fields 3
Posterior obliques 3
SBRT 7 Treatment planning technique depends on treatment
device used.
IMRT 6
Proton therapy to the bone metastasis 2
Rating Scale: 1,2,3: usually not appropriate; 4,5,6: may be appropriate; 7,8,9: usually appropriate.
CT, computed tomography; EBRT, external beam radiation therapy; IMRT, intensity-modulated radiation therapy; KPS, Karnofsky
performance status; OI, osteoclast inhibitors; SBRT, stereotactic body radiation therapy.
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therapies, including radiopharmaceuticals, could be given
either as an adjuvant or alone if surgery is not a practical
approach. Third-line chemotherapy with erlotinib may be
considered for individuals who have a good performance
status and who have not had prior exposure to erlotinib or
gefitinib. There are insufficient data addressing use of addi-
tional cytotoxic drugs; considerations may be given to clinical
trials and best supportive care.19 (See Table 4.)
Variant 5 Discussion
This patient has a good performance status, a relatively
long life expectancy, and a solitary site of painful metastasis
in a vertebra without canal involvement. This clinical sce-
nario qualifies as a case of oligometastasis.28 The optimal
management of oligometastases is an active area of re-
search. Investigations of site-specific localized therapy
Table 5. Variant 5
Clinical Condition: Spinal Bone Metastases
A 56-year-old postmenopausal woman with ER positive/PR positive and HER2 negative breast cancer and a KPS of 90.
At diagnosis, she developed a painful, solitary, biopsy-proven bone metastasis at T4 level with no canal involvement or
compression fracture/spinal instability and no other sites of metastasis.
Treatment Rating Comments
HT and EBRT 8
HT and OI and EBRT 8
Chemotherapy and HT and EBRT 5
Chemotherapy and HT and OI and EBRT 5
HT and OI 4
HT alone 4
Chemotherapy alone 3
Surgical intervention 3
Systemic radiopharmaceuticals alone 2
OI alone 2
Direct hospice placement 1 Life expectancy would be expected to be > 6 months.
Hospice after EBRT 1 Life expectancy would be expected to be > 6 months.
Radiation therapy dose
8Gy/1 fraction 8
20Gy/5 fractions 8
30Gy/10 fractions 8
35Gy/14 fractions 5 There may be a potential survival benefit to aggressive
local therapy of oligometastasis but more data are
needed to better define the role of this approach.
40Gy/20 fractions 5 There may be a potential survival benefit to aggressive
local therapy of oligometastasis but more data are
needed to better define the role of this approach.
Treatment planning
CT simulation 8 CT simulation is mandatory if SBRT is offered because
sophisticated dose planning is required.
Fluoroscopic simulation 8
Clinical simulation 5
Posterior field only 6 The depth of the spinal segments involved and photon
energy used are to be considered if this technique is
used. The skin dose is a concern for this patient who
is expected to have more favorable prognosis as
spinal surgery may be needed in the later course of
her disease.
Anterior/posterior fields 7
Posterior obliques 7 This technique can help preserve skin if spinal surgery
comes into play in the later course of disease but it
will result in higher lung doses.
SBRT No consensus There may be a potential survival benefit to aggressive
local therapy of oligometastasis but more data are
needed to better define the role of SBRT in this type
of clinical scenario.
IMRT 2
Proton therapy to the bone metastasis 1
Rating Scale: 1,2,3: usually not appropriate; 4,5,6: may be appropriate; 7,8,9: usually appropriate.
CT, computed tomography; EBRT, external beam radiation therapy; ER, estrogen receptor; HT, hormonal therapy; IMRT, intensity-
modulated radiation therapy; KPS, Karnofsky performance status; OI, osteoclast inhibitors; PR, progesterone receptor; SBRT, stereotactic
body radiation therapy.
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compared with a more systemic approach with or without
localized therapy are ongoing. Some have argued that pa-
tients with minimal sites of bone-only metastatic disease
(deemed ‘‘oligometastatic’’) may be treated with curative
intent, although the data to confirm that stance are still
limited. The use of HT and OI, with or without sequential
EBRT, is regarded as one of the reasonable treatment op-
tions. For this ER positive/PR positive tumor, where there is
no visceral involvement, a localized therapy may be con-
sidered, ideally as part of a clinical trial. Systemic therapy is
typically administered due to the likelihood of systemic
involvement.29 Surgical intervention is regarded as less
appropriate given the absence of spinal cord compression or
spinal instability and alternative methods of providing site-
specific disease control. Systemic radiopharmaceuticals
are regarded as the least appropriate and have not been
formally studied in the setting of newly diagnosed oligo-
metastatic disease.
If EBRT is not administered to the spine at this time, then
very close monitoring of the patient would be required to
monitor for pain, and for early symptoms of spinal cord
compression. Because this patient’s survival is likely to be
measured in years, hospice placement is deemed an inap-
propriate option.
The RT dose fractionation prescribed varies from those for
long bones. Fractionation schedules ranging from a single
8Gy fraction to 40Gy in 20 fractions are all considered ap-
propriate.30–33 CT simulation to accurately include the in-
volved vertebrae and account for body habitus in EBRT dose
calculation is most desirable. Fluoroscopic simulation is re-
garded as a reasonable alternative. Common EBRT field
arrangements, AP/PA and PA alone, are considered
Table 6. Variant 6
Clinical Condition: Spinal Bone Metastases
A 45-year-old woman with metastatic renal cell carcinoma, involving her lungs and T9, and a KPS of 90, received sunitinib
and developed progressive single spinal metastasis at T9 with no canal involvement or compression fracture. Her other
extraspinal metastases in the lungs and right adrenal were stable.
Treatment Rating Comments
Systemic therapy and EBRT 7
Systemic therapy and EBRT and OI 7
Systemic therapy and OI 5
Systemic therapy alone 4
EBRT alone 3
Surgical intervention 3
OI alone 3
Systemic radiopharmaceuticals alone 2
Direct hospice placement 2
Hospice after EBRT 2
Radiation therapy dose
8Gy/1 fraction 5
20Gy/5 fractions 7
30Gy/10 fractions 7
35Gy/14 fractions 7
40Gy/20 fractions 5
20–30Gy/5 fractions (SBRT) 7 Spinal cord tolerance permitting.
18–27Gy/3 fractions (SBRT) 7 Spinal cord tolerance permitting.
15–24Gy/1 fraction (SBRT) 7 Spinal cord tolerance permitting.
Treatment planning
CT simulation 9 CT simulation is mandatory if SBRT is offered because
sophisticated dose planning is required.
Fluoroscopic simulation 7
Clinical simulation 5
Posterior field only 6 The depth of the spinal segments involved and photon energy used
are to be considered if this technique is used.
Anterior/posterior fields 7
Posterior obliques 7 This technique can help preserve skin if spinal surgery comes into
play in the later course of disease but it will result in higher lung
doses.
SBRT 7 Because renal cell carcinoma is radioresistant histology, there may
be a benefit to using SBRT, which delivers ablative doses of
radiation to the spinal metastatic lesion.
IMRT 4
Proton therapy to the bone
metastasis
1
Rating Scale: 1,2,3: usually not appropriate; 4,5,6: may be appropriate; 7,8,9: usually appropriate.
CT, computed tomography; EBRT, external beam radiation therapy; IMRT, intensity-modulated radiation therapy; KPS, Karnofsky
performance status; OI, osteoclast inhibitors; SBRT, stereotactic body radiation therapy.
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appropriate. Posterior oblique treatment is favored as it is an
easy, relatively conformal dosimetric approach that can reduce
the skin dose, and thismaybe beneficial if spinal surgery comes
into play in the later course of disease. However, it can also
result in higher lung dose. The treating physician will need to
judge the risk and benefit of each technique in each individual
patient. In this setting of spinal oligometastasis and the absence
of extraspinal metastasis, if aggressive local therapy is part of
the treatment regimen, SBRT or IMRT aimed at delivering a
higher biologically effective dose to improve local control may
be considered appropriate, particularly as part of a clinical
trial.6,8 The relatively limited availability andmuch higher cost
render proton beam therapy not appropriate. (See Table 5.)
Variant 6 Discussion
This patient has a good performance status and a single site
of painful and progressive metastasis in a vertebra without
canal involvement. Standard analgesics should be used for
initial pain control. Renal cell carcinoma is regarded as a
radioresistant histology andmay not be as responsive to EBRT
in the palliative dose range, although some palliative response
has been observed.34,35 The use of EBRT with sequential sys-
temic therapy with or without OI is deemed appropriate.
Surgical intervention is not routinely offered in the absence of
spinal cord compression or spinal instability. Systemic radio-
pharmaceuticals are regarded as the least appropriate.
Especially in this symptomatic spine lesion where disease
progression under systemic therapy alone could incur the risk
of spinal cord compression, the benefit of adding EBRT to
systemic therapy in a sequential fashion is again emphasized.
If EBRT is not administered to the spine, then very close
monitoring of the patient would be required to assess for pain,
and for early symptoms of spinal cord compression.
Given the radioresistant nature of renal cell carcinoma, a
more aggressive dose regimen is deemed appropriate.34,36 If
SBRT is available, it is best used in a clinical trial setting. SBRT
regimens using 1–5 fractions are deemed appropriate. This
should be combined with systemic therapy sequentially be-
cause the systemic disease still needs to be addressed. Frac-
tionation schedules delivering a higher dose, such as 30Gy in
10 fractions, 35Gy in 14 fractions, or 40Gy in 20 fractions, are
deemed appropriate.30–33 SBRT dose regimens include 16–
24Gy in 1 fraction, 24–27Gy in 3 fractions, and 30Gy in 5
fractions, and they are all regarded as appropriate provided
that spinal cord tolerance is respected.37 CT simulation is
required to accurately include the involved vertebrae and ac-
count for body habitus in SBRTdose calculation. CT simulation
is also desirable if EBRT is used. Fluoroscopic simulation is
regarded as a reasonable alternative. Common EBRT field ar-
rangements, AP/PA and PA alone, are considered appropri-
ate. A posterior oblique treatment approach is most favored as
it is an easy, relatively conformal, dosimetric approach that can
reduce the volume of the RT dose administered to the esoph-
agus within the EBRT field. The relatively limited availability
renders proton beam therapy not practical. (See Table 6.)
Summary
 EBRT successfully provides rapid palliative relief
from painful spinal bone metastases in the majority of
cases.
 The acute side effects of palliative EBRT are usually
minimal and self-limiting, whereas long-term side ef-
fects are uncommon and often irrelevant in a patient
group with limited life expectancy.
 In good performance status patients with epidural spi-
nal cord compression, surgical decompression should be
considered, and this should be followed by EBRT if no
EBRT has been given before in the same area.
 Prospective randomized trials have proven that equiv-
alent pain relief can be achieved with varied fraction-
ation schemes including a single 8Gy, 20Gy in 5
fractions, 24Gy in 6 fractions, or 30Gy in 10 fractions.
Prolonged courses are associated with a lower incidence
of retreatment, whereas shorter courses maximize pa-
tient and caregiver convenience.
 Reirradiation of spinal metastasis may be achieved us-
ing highly conformal techniques such as SBRT, IMRT,
and proton beam therapy, although retreatment can
carry a higher risk of radiation myelitis. Ideally, if there
is a clinical trial available, patients should be enrolled to
be treated on protocol. Surgical intervention should be
considered in patients with previously irradiated spinal
metastases causing severe pain or spinal compression.
 Highly conformal techniques such as SBRT, IMRT, and
proton beam therapy for spinal cord compression are
best tested in a clinical trial setting.
 There may be a potential survival benefit to aggressive
local therapy of oligometastasis but more data are nee-
ded to better define the role of highly conformal RT
techniques that allow for radiation dose escalation in
this type of clinical scenario.
 Other treatments such as analgesics, including narcotic
analgesics and steroids, should be used initially for pain
control in most cases.
 OI can be incorporated into palliative care of skeletal
complications from spinal metastasis.
 Management of metastatic bone disease is palliative. A
multidisciplinary team of care providers should be
available to the patient, including the palliative care
team. Goals of care should be defined with the patient.
Hospice referral should be considered if the patient’s life
expectancy is £ 6 months.
For additional information on ACR Appropriateness Cri-
teria, refer to the ACR website (www.acr.org/ac).
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